Goodwin, Latham Steer $2.8B Drug Discovery SPAC Deal

Law360 (June 9, 2021, 5:52 PM EDT) -- Boston-based drug discovery startup Valo Health LLC said Wednesday that it plans to go public at a valuation of about $2.8 billion through a merger with a blank check company, in a deal led by Goodwin Procter LLP and Latham & Watkins LLP.

Valo Health specializes in applying machine learning to speed up and streamline drug discovery and development, according to its website. The company says it has a pipeline of two clinical-stage drugs and more than 15 earlier-stage candidates. Its targets include cancer and cardiovascular disease.

As a blank-check company, or special purpose acquisition company, Khosla Ventures Acquisition Co. raised...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!